Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review
Translational Lung Cancer Research · 2023-02 · 12 (2) · 369-378
DOI: 10.21037/tlcr-22-656 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Lung Cancer Research, 2023-02. Verfasst von Grace Chazan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Zitieren
APA
Chazan, G., & Solomon, B. J. (2023). Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review. Translational Lung Cancer Research, 12(2), 369-378. https://doi.org/10.21037/tlcr-22-656
Vancouver
Chazan G, Solomon BJ. Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review. Translational Lung Cancer Research. 2023;12(2):369-378. doi:10.21037/tlcr-22-656
BibTeX
@article{Chazan2023,
author = {Chazan, Grace and Solomon, Benjamin J},
title = {Optimal first-line treatment for metastatic ALK+ non-small cell lung cancer—a narrative review},
journal = {Translational Lung Cancer Research},
year = {2023},
volume = {12},
number = {2},
pages = {369--378},
doi = {10.21037/tlcr-22-656}
}
EUVIMED